OTCMKTS:RNUGF - ReNeuron Group Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.07 0.00 (0.00 %) (As of 07/20/2018 04:00 PM ET)Previous Close$1.07Today's Range$1.07 - $1.0752-Week Range$0.0160 - $1.35VolumeN/AAverage Volume24 shsMarket Capitalization$33.86 millionP/E Ratio-1.07Dividend YieldN/ABeta-364.69 Company ProfileHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom. Receive RNUGF News and Ratings via Email Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical SymbolOTCMKTS:RNUGF CUSIPN/A Webwww.reneuron.com Phone44-20-3819-8400 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-1.07 Forward P/E Ratio-1.23 P/E GrowthN/A Sales & Book Value Annual Sales$60,000.00 Price / Sales564.43 Cash FlowN/A Price / CashN/A Book Value$2.20 per share Price / Book0.49 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares31,650,000Market Cap$33.86 ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions What is ReNeuron Group's stock symbol? ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF." What is the consensus analysts' recommendation for ReNeuron Group? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReNeuron Group in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include LONMIN PLC/S (LNMIY), INTERSERVE PLC/ADR (ISVJY), Carillion (CIOIF), FREEDOM Bk OF V/SH SH (FDVA), SUNDANCE ENERGY/S (SNDE), VICTORIA OIL & GAS (VCOGF), AVITA Med Ltd/S (AVMXY), Companhia Energética de Săo Paulo (CESDY), Alexium International Group (AXXIY), OLEO E GAS PART/S (OGXPY), Wentworth Resource (WENTF), PDG Rlty S A EM/S (PDGRY), WHITE ENERGY Co/S (WECFY), Orosur Mining (OROXF) and Zadar Ventures (ZADDF). Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the folowing people: Mr. Olav Hellebø, Chief Exec. Officer and Director (Age 53)Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 55)Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 67)Dr. Randolph Corteling, Head of ResearchMs. Sharon Grimster FSB, AFIChemE, BSc, DMS, VP of Devel. & GM of Wales (Age 59) Has ReNeuron Group been receiving favorable news coverage? News articles about RNUGF stock have been trending somewhat positive on Friday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ReNeuron Group earned a news impact score of 0.15 on Accern's scale. They also gave headlines about the company an impact score of 46.52 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of ReNeuron Group? Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ReNeuron Group's stock price today? One share of RNUGF stock can currently be purchased for approximately $1.07. How big of a company is ReNeuron Group? ReNeuron Group has a market capitalization of $33.86 million and generates $60,000.00 in revenue each year. The company earns $-20,350,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-20-3819-8400. MarketBeat Community Rating for ReNeuron Group (OTCMKTS RNUGF)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 41 (Vote Outperform)Underperform Votes: 51 (Vote Underperform)Total Votes: 92MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RNUGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNUGF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?